Details of the Drug

General Information of Drug (ID: DMX4GND)

Drug Name

Meperidine

Synonyms

Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]

Therapeutic Class

Anesthetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

247.33

Topological Polar Surface Area (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 4.9 mL/min/kg [3]
Elimination: 13% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 5 hours [3]
Metabolism: The drug is metabolized via the liver [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 60.64524 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.42% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.3 L/kg [3]
Water Solubility: The ability of drug to dissolve in water is measured as 3.22 mg/mL [2]

Chemical Identifiers

Formula: C15H21NO2
IUPAC Name: ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
Canonical SMILES: CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2
InChI: InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
InChIKey: XADCESSVHJOZHK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4058
ChEBI ID: CHEBI:6754
CAS Number: 57-42-1
DrugBank ID: DB00454
TTD ID: D00UYE
VARIDT ID: DR00016
INTEDE ID: DR1024
ACDINA ID: D00397

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[6], [7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Meperidine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Meperidine and Pentazocine.	Pain [MG30-MG3Z]	[64]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Meperidine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[65]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Meperidine and Butorphanol.	Pain [MG30-MG3Z]	[64]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Meperidine and Oxymorphone.	Pain [MG30-MG3Z]	[66]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Meperidine and Levorphanol.	Pain [MG30-MG3Z]	[66]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Meperidine and Dezocine.	Pain [MG30-MG3Z]	[64]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Meperidine and Flavoxate.	Pain [MG30-MG3Z]	[67]
Nalbuphine	DMOSQGU	Major	Additive hypotensive effects by the combination of Meperidine and Nalbuphine.	Pain [MG30-MG3Z]	[64]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Meperidine and Buprenorphine.	Pain [MG30-MG3Z]	[64]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Meperidine and Hydrocodone.	Pain [MG30-MG3Z]	[66]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Meperidine and Oxycodone.	Pain [MG30-MG3Z]	[66]
-----------


⏷ Show the Full List of 11 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Meperidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Meperidine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[68]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Meperidine and Oliceridine.	Acute pain [MG31]	[66]
Marinol	DM70IK5	Moderate	Additive CNS depression effects by the combination of Meperidine and Marinol.	Anorexia nervosa [6B80]	[69]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Meperidine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[70]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Meperidine and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[71]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Meperidine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[66]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Meperidine and Halazepam.	Anxiety disorder [6B00-6B0Z]	[66]
Chlordiazepoxide	DMTN5XI	Major	Additive CNS depression effects by the combination of Meperidine and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[66]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Meperidine and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[66]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Meperidine and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[66]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Meperidine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[72]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Meperidine and Linezolid.	Bacterial infection [1A00-1C4Z]	[73]
Retigabine	DMGNYIH	Moderate	Additive CNS depression effects by the combination of Meperidine and Retigabine.	Behcet disease [4A62]	[69]
Lamotrigine	DM8SXYG	Moderate	Additive CNS depression effects by the combination of Meperidine and Lamotrigine.	Bipolar disorder [6A60]	[69]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Meperidine and Cariprazine.	Bipolar disorder [6A60]	[66]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Meperidine and Loperamide.	Bowel habit change [ME05]	[74]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Meperidine caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[75]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Meperidine and Dihydrocodeine.	Chronic pain [MG30]	[71]
Levetiracetam	DMTGDN8	Moderate	Additive CNS depression effects by the combination of Meperidine and Levetiracetam.	Chronic pain [MG30]	[69]
Levobupivacaine	DM783CH	Minor	Increased plasma concentration of Meperidine and Levobupivacaine due to competitive binding of plasma proteins.	Corneal disease [9A76-9A78]	[76]
Propofol	DMB4OLE	Moderate	Additive cardiorespiratory depression effects by the combination of Meperidine and Propofol.	Corneal disease [9A76-9A78]	[77]
Ketamine	DMT5HA4	Moderate	Additive CNS depression effects by the combination of Meperidine and Ketamine.	Corneal disease [9A76-9A78]	[69]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Meperidine and Ethanol.	Cystitis [GC00]	[78]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Meperidine and Sertraline.	Depression [6A70-6A7Z]	[72]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Meperidine and Trimipramine.	Depression [6A70-6A7Z]	[72]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Meperidine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[70]
Imipramine	DM2NUH3	Major	Additive serotonergic effects by the combination of Meperidine and Imipramine.	Depression [6A70-6A7Z]	[72]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of Meperidine and Fluoxetine.	Depression [6A70-6A7Z]	[72]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Meperidine and Nortriptyline.	Depression [6A70-6A7Z]	[72]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Meperidine and Vilazodone.	Depression [6A70-6A7Z]	[72]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Meperidine and Nefazodone.	Depression [6A70-6A7Z]	[72]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Meperidine and Paroxetine.	Depression [6A70-6A7Z]	[72]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Meperidine and Selegiline.	Depression [6A70-6A7Z]	[68]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Meperidine and Duloxetine.	Depression [6A70-6A7Z]	[72]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Meperidine and Isocarboxazid.	Depression [6A70-6A7Z]	[68]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Meperidine and Milnacipran.	Depression [6A70-6A7Z]	[72]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Meperidine and Escitalopram.	Depression [6A70-6A7Z]	[72]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Meperidine and Tranylcypromine.	Depression [6A70-6A7Z]	[68]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Meperidine and Desvenlafaxine.	Depression [6A70-6A7Z]	[72]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Meperidine and OPC-34712.	Depression [6A70-6A7Z]	[66]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Meperidine and Phenelzine.	Depression [6A70-6A7Z]	[68]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Meperidine and Clomipramine.	Depression [6A70-6A7Z]	[72]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Meperidine and Trazodone.	Depression [6A70-6A7Z]	[72]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Meperidine and Amoxapine.	Depression [6A70-6A7Z]	[72]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Meperidine and Doxepin.	Depression [6A70-6A7Z]	[72]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Meperidine and Maprotiline.	Depression [6A70-6A7Z]	[69]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Meperidine and Esketamine.	Depression [6A70-6A7Z]	[79]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Meperidine and Mepenzolate.	Digestive system disease [DE2Z]	[67]
Oxybutynine	DMJPBAX	Moderate	Additive CNS depression effects by the combination of Meperidine and Oxybutynine.	Discovery agent [N.A.]	[67]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Meperidine and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[71]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Meperidine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[72]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Meperidine and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[66]
Zonisamide	DM0DTF7	Moderate	Additive CNS depression effects by the combination of Meperidine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[69]
Primidone	DM0WX6I	Major	Increased metabolism of Meperidine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Felbamate	DM1V5ZS	Moderate	Additive CNS depression effects by the combination of Meperidine and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[69]
Oxcarbazepine	DM5PU6O	Moderate	Additive CNS depression effects by the combination of Meperidine and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[69]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Meperidine caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[80]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Meperidine and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[81]
Cenobamate	DMGOVHA	Moderate	Additive CNS depression effects by the combination of Meperidine and Cenobamate.	Epilepsy/seizure [8A61-8A6Z]	[69]
Tiagabine	DMKSQG0	Moderate	Additive CNS depression effects by the combination of Meperidine and Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[69]
Stiripentol	DMMSDOY	Moderate	Additive CNS depression effects by the combination of Meperidine and Stiripentol.	Epilepsy/seizure [8A61-8A6Z]	[69]
Phenacemide	DMOHS9P	Moderate	Additive CNS depression effects by the combination of Meperidine and Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[69]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Meperidine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[80]
Paramethadione	DMR5ZUP	Moderate	Additive CNS depression effects by the combination of Meperidine and Paramethadione.	Epilepsy/seizure [8A61-8A6Z]	[69]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Meperidine and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[66]
Lacosamide	DMVM6QR	Moderate	Additive CNS depression effects by the combination of Meperidine and Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[69]
Rufinamide	DMWE60C	Moderate	Additive CNS depression effects by the combination of Meperidine and Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[69]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Meperidine caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[80]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Meperidine and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[74]
Vigabatrin	DMYT0OG	Moderate	Additive CNS depression effects by the combination of Meperidine and Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[69]
Carbamazepine	DMZOLBI	Moderate	Additive CNS depression effects by the combination of Meperidine and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[69]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Meperidine and Cannabidiol.	Epileptic encephalopathy [8A62]	[69]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Meperidine and Dantrolene.	Fever [MG26]	[66]
Solifenacin	DMG592Q	Moderate	Additive CNS depression effects by the combination of Meperidine and Solifenacin.	Functional bladder disorder [GC50]	[67]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Meperidine and Tolterodine.	Functional bladder disorder [GC50]	[67]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Meperidine and Propantheline.	Gastric ulcer [DA60]	[67]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Meperidine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[82]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Meperidine and Brimonidine.	Glaucoma [9C61]	[83]
Isoniazid	DM5JVS3	Moderate	Additive hypotensive effects by the combination of Meperidine and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[84]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Meperidine and Procarbazine.	Hodgkin lymphoma [2B30]	[68]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Meperidine and Suvorexant.	Insomnia [7A00-7A0Z]	[66]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Meperidine and Ramelteon.	Insomnia [7A00-7A0Z]	[66]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Meperidine and Flurazepam.	Insomnia [7A00-7A0Z]	[66]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Meperidine and Triazolam.	Insomnia [7A00-7A0Z]	[66]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Meperidine and Zaleplon.	Insomnia [7A00-7A0Z]	[66]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Meperidine and Propiomazine.	Insomnia [7A00-7A0Z]	[66]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Meperidine and Tasimelteon.	Insomnia [7A00-7A0Z]	[66]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Meperidine and Paraldehyde.	Insomnia [7A00-7A0Z]	[66]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Meperidine and ITI-007.	Insomnia [7A00-7A0Z]	[66]
Nabilone	DMVRYT2	Moderate	Additive CNS depression effects by the combination of Meperidine and Nabilone.	Insomnia [7A00-7A0Z]	[69]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Meperidine and Quazepam.	Insomnia [7A00-7A0Z]	[66]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Meperidine and Estazolam.	Insomnia [7A00-7A0Z]	[66]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Meperidine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[85]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Meperidine and Clidinium.	Irritable bowel syndrome [DD91]	[67]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Meperidine and Dicyclomine.	Irritable bowel syndrome [DD91]	[67]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Meperidine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[66]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Meperidine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[79]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Meperidine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[86]
Dexmedetomidine	DM93L4X	Moderate	Additive CNS depression effects by the combination of Meperidine and Dexmedetomidine.	Mood/affect symptom [MB24]	[69]
Midazolam	DMXOELT	Moderate	Additive CNS depression effects by the combination of Meperidine and Midazolam.	Mood/affect symptom [MB24]	[69]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Meperidine and Thalidomide.	Multiple myeloma [2A83]	[87]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Meperidine due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[88]
Promethazine	DM6I5GR	Moderate	Additive CNS depression effects by the combination of Meperidine and Promethazine.	Nausea/vomiting [MD90]	[69]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Meperidine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[89]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Meperidine and Granisetron.	Nausea/vomiting [MD90]	[90]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Meperidine and Dolasetron.	Nausea/vomiting [MD90]	[90]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Meperidine and Ondansetron.	Nausea/vomiting [MD90]	[90]
E-2007	DMJDYNQ	Moderate	Additive CNS depression effects by the combination of Meperidine and E-2007.	Neuropathy [8C0Z]	[69]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Meperidine and Bupropion.	Nicotine use disorder [6C4A]	[91]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Meperidine and Sibutramine.	Obesity [5B80-5B81]	[92]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Meperidine and Lorcaserin.	Obesity [5B80-5B81]	[93]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Meperidine and Dexfenfluramine.	Obesity [5B80-5B81]	[72]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Meperidine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[71]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Meperidine and Apraclonidine.	Optic nerve disorder [9C40]	[83]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Meperidine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[79]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Meperidine and Safinamide.	Parkinsonism [8A00]	[68]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Meperidine and Rasagiline.	Parkinsonism [8A00]	[68]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Meperidine and Biperiden.	Parkinsonism [8A00]	[94]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Meperidine and Pimavanserin.	Parkinsonism [8A00]	[66]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Meperidine and Orphenadrine.	Parkinsonism [8A00]	[66]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Meperidine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[95]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Meperidine and Methylscopolamine.	Peptic ulcer [DA61]	[67]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Meperidine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[69]
Fluphenazine	DMIT8LX	Major	Additive CNS depression effects by the combination of Meperidine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[96]
Triflupromazine	DMKFQJP	Major	Additive CNS depression effects by the combination of Meperidine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[66]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Meperidine and Quetiapine.	Schizophrenia [6A20]	[96]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Meperidine and Mesoridazine.	Schizophrenia [6A20]	[96]
Thioridazine	DM35M8J	Major	Additive CNS depression effects by the combination of Meperidine and Thioridazine.	Schizophrenia [6A20]	[66]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Meperidine and Aripiprazole.	Schizophrenia [6A20]	[66]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Meperidine and Iloperidone.	Schizophrenia [6A20]	[66]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Meperidine and Paliperidone.	Schizophrenia [6A20]	[66]
Haloperidol	DM96SE0	Major	Additive CNS depression effects by the combination of Meperidine and Haloperidol.	Schizophrenia [6A20]	[66]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Meperidine and Perphenazine.	Schizophrenia [6A20]	[66]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Meperidine and Molindone.	Schizophrenia [6A20]	[66]
Chlorpromazine	DMBGZI3	Major	Additive CNS depression effects by the combination of Meperidine and Chlorpromazine.	Schizophrenia [6A20]	[96]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Meperidine and Thiothixene.	Schizophrenia [6A20]	[96]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Meperidine and Trifluoperazine.	Schizophrenia [6A20]	[66]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Meperidine and Asenapine.	Schizophrenia [6A20]	[66]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Meperidine and Pimozide.	Schizophrenia [6A20]	[66]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Meperidine and Fentanyl.	Sensation disturbance [MB40]	[66]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Meperidine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[79]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Meperidine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[97]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Meperidine due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[88]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Meperidine and Tizanidine.	Tonus and reflex abnormality [MB47]	[66]
Atropine	DMEN6X7	Moderate	Additive antimotility effects by the combination of Meperidine and Atropine.	Unspecific substance harmful effect [NE6Z]	[67]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Meperidine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[69]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Meperidine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[98]
-----------


⏷ Show the Full List of 147 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 27	E00381	83511	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Meperidine 150 mg tablet	150 mg	Oral Tablet	Oral
Meperidine 75 mg tablet	75 mg	Oral Tablet	Oral
Meperidine 100 mg tablet	100 mg	Oral Tablet	Oral
Meperidine 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
7	Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype. Anesthesiology. 2002 Jun;96(6):1420-6.
8	Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40.
9	Is meperidine the drug that just won't die? J Pediatr Pharmacol Ther. 2011 Jul;16(3):167-9.
10	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.
11	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
12	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
31	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
32	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
33	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
34	Drugs that may have potential CYP2B6 interactions.
35	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
36	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
37	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
38	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
39	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
40	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
41	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
42	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
43	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
44	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
45	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
46	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
47	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
48	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
49	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
50	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
51	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
52	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
53	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
54	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
55	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
56	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
57	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
58	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
59	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
60	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
61	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
62	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
63	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
64	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
65	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
66	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
67	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
68	Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]
69	Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
70	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
71	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
72	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
73	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
74	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
75	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
76	Ghoneim MM, Pandya H "Plasma protein binding of bupivacaine and its interaction with other drugs in man." Br J Anaesth 46 (1974): 435-8. [PMID: 4458761]
77	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
78	Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
79	Cerner Multum, Inc. "Australian Product Information.".
80	Pond SM, Kretschzmar KM "Effect of phenytoin on meperidine clearance and normeperidine formation." Clin Pharmacol Ther 30 (1981): 680-6. [PMID: 7297025]
81	Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
82	Guay DR, Meatherall RC, Chalmers JL, Grahame GR "Cimetidine alters pethidine disposition in man." Br J Clin Pharmacol 18 (1984): 907-14. [PMID: 6529532]
83	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
84	Gannon RG, Pearsall W, Rowley R "Isoniazid, meperidine, and hypotension." Ann Intern Med 99 (1983): 415. [PMID: 6614704]
85	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
86	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
87	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
88	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
89	Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
90	Canadian Pharmacists Association.
91	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
92	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
93	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
94	Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
95	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
96	Cerner Multum, Inc. "Canadian Product Information.".
97	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
98	Hoffman JC, Smith TC "The respiratory effects of meperidine and propiomazine in man." Anesthesiology 32 (1970): 325-31. [PMID: 4392394]